Form: 8-K

Current report filing

March 11, 2005

Documents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): March 10, 2005

 

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (804) 648-3820

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 8.01. OTHER EVENTS.

 

On March 10, 2005, Commonwealth Biotechnologies, Inc. announced the receipt of additional contract awards. A copy of the press release is attached as an exhibit hereto.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

 

Not Applicable.

 

(b) Pro forma financial information.

 

Not Applicable.

 

(c) Exhibits.

 

99.1   On March 10, 2005, Commonwealth Biotechnologies, Inc. announced the receipt of additional contract awards. A copy of the press release is attached as an exhibit hereto.

 

2

Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Robert B. Harris, Ph.D.
    Robert B. Harris, Ph.D.
    President and Chief Executive Officer

 

Dated: March 11, 2005

 

3

EXHIBIT INDEX

 

Number
  

Description of Exhibit
99.1   On March 10, 2005, Commonwealth Biotechnologies, Inc. announced the receipt of additional contract awards. A copy of the press release is attached as an exhibit hereto.

 

4